(R,R)-BD-AcAc 2((R,R)-Ketone Ester) 是一种酮单酯，可作为口服营养酮的来源。小鼠口服 (R,R)-BD-AcAc 2 后可提高血浆 β-羟基丁酸和乙酰乙酸水平、血糖、血液钠离子水平和血肌酐水平。(R,R)-BD-AcAc 2 可在一定程度上预防脓毒症小鼠的肌无力。(R,R)-BD-AcAc 2 具有提高动物机体运动能力和耐力的潜力。(R,R)-BD-AcAc 2 还可用于研究帕金森病或糖尿病。
| 生物活性 | (R,R)-BD-AcAc 2 ((R,R)-Ketone Ester), a ketone monoester, can be used as a source of oral nutritional ketones. (R,R)-BD-AcAc 2 can elevate plasma levels of β-hydroxybutyrate and acetoacetate, blood glucose, blood Na+levels and blood creatinine levels after oral administration in mice. (R,R)-BD-AcAc 2 can partly prevent muscle weakness in septic mice. (R,R)-BD-AcAc 2 has potential to improve exercise performance and endurance in animal body. (R,R)-BD-AcAc 2 can also be used to research Parkinson’s disease or diabetes[1][2][3]. |
体内研究
(In Vivo) | (R,R)-BD-AcAc 2 (D-3HHB) increases specific muscle force, moderately raises blood glucose concentrations, lowersAldh3b2gene expression, increases blood Na+levels and blood creatinine levels, and reduces plasma free fatty acid concentrations[1].
| Animal Model: | Septic mice[1] | | Dosage: | 10, 20, 40 and 80 mmol/kg/day | | Administration: | PO | | Result: | Increased specific muscle force as compared with placebo to 93% of healthy control levels at 40 mmol/kg/day.
Resulted in moderately higher blood glucose concentrations as compared with placebo at 40 mmol/kg/day.
LoweredAldh3b2gene expression than with placebo at 40 mmol/kg/day.
Evoked a moderate further increase in blood Na+levels and increased blood creatinine levels at 20 mmol/kg/day.
Reduced plasma free fatty acid concentrations by 10 or 20 mmol/kg/day.
Hepatic gene expression levels ofAldh1a7was also reduced by sepsis but increased by D-3HHB. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Pure form | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: H2O : 100 mg/mL(567.50 mM;Need ultrasonic) DMSO : 100 mg/mL(567.50 mM;Need ultrasonic) 配制储备液 | 1 mM | 5.6750 mL | 28.3752 mL | 56.7505 mL | | 5 mM | 1.1350 mL | 5.6750 mL | 11.3501 mL | | 10 mM | 0.5675 mL | 2.8375 mL | 5.6750 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 100 mg/mL (567.50 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 5.5 mg/mL (31.21 mM); Clear solution
此方案可获得 ≥ 5.5 mg/mL (31.21 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 5.5 mg/mL (31.21 mM); Clear solution
此方案可获得 ≥ 5.5 mg/mL (31.21 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 4. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 5.5 mg/mL (31.21 mM); Clear solution
此方案可获得 ≥ 5.5 mg/mL (31.21 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 55.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
